Koers IRLAB Therapeutics AB (publ) Nasdaq Stockholm
Aandelen
SE0012675361
Farmaceutische producten
Omzet 2023 | 5,68 mln. 530K 487K | Omzet 2024 * | 65,65 mln. 6,13 mln. 5,64 mln. | Marktkapitalisatie | 791 mln. 73,83 mln. 67,9 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -178 mln. -16,61 mln. -15,28 mln. | Nettowinst (verlies) 2024 * | -111 mln. -10,36 mln. -9,53 mln. | EV/omzet 2023 | 48,9 x |
Nettoliquiditeiten 2023 | 111 mln. 10,39 mln. 9,55 mln. | Nettoliquiditeiten 2024 * | 11,93 mln. 1,11 mln. 1,02 mln. | EV/omzet 2024 * | 11,9 x |
K/w-verhouding 2023 |
-2,19
x | K/w-verhouding 2024 * |
-4,95
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 57,48% |
Recentste transcriptie over IRLAB Therapeutics AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 01-01-13 |
Chief Executive Officer | 71 | 06-05-17 | |
Nicholas Waters
FOU | Founder | 62 | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 01-01-16 |
Rein Piir
BRD | Director/Board Member | 66 | 01-01-16 |
Chairman | 66 | 01-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,09% | 694 mld. | |
+29,39% | 593 mld. | |
-1,34% | 371 mld. | |
+20,34% | 331 mld. | |
+7,39% | 290 mld. | |
+14,25% | 239 mld. | |
-3,03% | 209 mld. | |
+10,02% | 209 mld. | |
+8,49% | 169 mld. |